GeneOne Life Science Inc (KO:011000) — Market Cap & Net Worth
Market Cap & Net Worth: GeneOne Life Science Inc (011000)
GeneOne Life Science Inc (KO:011000) has a market capitalization of $164.07 Million (₩242.10 Billion) as of August 4, 2026. Listed on the KO stock exchange, this Korea-based company holds position #17270 globally and #662 in its home market, demonstrating a 201.69% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying GeneOne Life Science Inc's stock price ₩2670.00 by its total outstanding shares 90673443 (90.67 Million). See GeneOne Life Science Inc capital reinvestment ratio to understand how much of operating cash flow is reinvested back into capital assets.
GeneOne Life Science Inc Market Cap History: 2015 to 2026
GeneOne Life Science Inc's market capitalization history from 2015 to 2026. Data shows change from $321.75 Million to $164.07 Million (-8.63% CAGR).
GeneOne Life Science Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how GeneOne Life Science Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.01x
GeneOne Life Science Inc's market cap is 0.01 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $353.32 Million | $31.37 Billion | -$15.60 Billion | 0.01x | N/A |
| 2017 | $193.56 Million | $27.17 Billion | -$23.73 Billion | 0.01x | N/A |
| 2018 | $142.14 Million | $34.29 Billion | -$11.90 Billion | 0.00x | N/A |
| 2019 | $88.28 Million | $41.24 Billion | -$7.62 Billion | 0.00x | N/A |
| 2020 | $864.10 Million | $41.50 Billion | -$18.65 Billion | 0.02x | N/A |
| 2021 | $995.46 Million | $38.70 Billion | -$15.95 Billion | 0.03x | N/A |
| 2022 | $438.74 Million | $48.72 Billion | -$38.15 Billion | 0.01x | N/A |
| 2023 | $174.51 Million | $40.20 Billion | -$77.77 Billion | 0.00x | N/A |
| 2024 | $129.96 Million | $35.72 Billion | -$48.54 Billion | 0.00x | N/A |
| 2025 | $120.38 Million | $23.04 Billion | -$51.85 Billion | 0.01x | N/A |
Competitor Companies of 011000 by Market Capitalization
Companies near GeneOne Life Science Inc in the global market cap rankings as of August 4, 2026.
Key companies related to GeneOne Life Science Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #423 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #541 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- UCB SA (BR:UCB): Ranked #564 globally with a market cap of $47.34 Billion USD ( €40.49 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $470.72 |
| #423 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $759.24 |
| #541 | Argen-X | BR:ARGX | $49.55 Billion | €722.20 |
| #564 | UCB SA | BR:UCB | $47.34 Billion | €221.40 |
GeneOne Life Science Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, GeneOne Life Science Inc's market cap moved from $321.75 Million to $ 164.07 Million, with a yearly change of -8.63%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩164.07 Million | +36.29% |
| 2025 | ₩120.38 Million | -7.38% |
| 2024 | ₩129.96 Million | -25.53% |
| 2023 | ₩174.51 Million | -60.22% |
| 2022 | ₩438.74 Million | -55.93% |
| 2021 | ₩995.46 Million | +15.20% |
| 2020 | ₩864.10 Million | +878.87% |
| 2019 | ₩88.28 Million | -37.90% |
| 2018 | ₩142.14 Million | -26.57% |
| 2017 | ₩193.56 Million | -45.22% |
| 2016 | ₩353.32 Million | +9.81% |
| 2015 | ₩321.75 Million | -- |
End of Day Market Cap According to Different Sources
On Aug 4th, 2026 the market cap of GeneOne Life Science Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $164.07 Million USD |
| MoneyControl | $164.07 Million USD |
| MarketWatch | $164.07 Million USD |
| marketcap.company | $164.07 Million USD |
| Reuters | $164.07 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About GeneOne Life Science Inc
GeneOne Life Science, Inc., a biopharmaceutical company, engages in the research, development, and contract manufacturing of nucleic acid-based biopharmaceuticals. Its small molecule pipeline comprises GLS-1027, which is in Phase I clinical trial for treatment of nephropathy and inflammatory diseases; GLS-1200 that is in Phase II clinical trial to treat Rhinosinusitis; GLS-1027 and GLS-1200, whic… Read more